ArticleJACC. Case reports2026
Coronary Sinus Reducer Implantation in a Patient With Cardiac Resynchronization Therapy and Defibrillator.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Successful coronary sinus reducer implantation in a patient with a pre-existing left ventricular pacing lead: a case report.European heart journal. Case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA coronary sinus reducer (CSR) is an hourglass-shaped stainless steel stent that is percutaneously inserted in the coronary sinus. It improves myocardial perfusion by narrowing the coronary sinus and dilating the arterioles into the ischemic subendocardium. CASE SUMMARY: A 79-year-old man with chronic coronary syndrome, previously implanted with a cardiac resynchronization therapy and defibrillator (CRT-D), presented to our hospital for refractory angina. He was under optimized medical therapy and not amenable to further revascularization. Therefore, a CSR was implanted. DISCUSSION: CSR implantation in patients with CRT-D is not currently defined by any guidelines. It might be a challenging procedure that can damage or dislocate the resynchronization lead, and data in literature are limited to case reports. TAKE-HOME MESSAGES: Refractory angina is a serious epidemiologic issue that greatly limits patients' quality of life. CSR implantation appears to be a safe and effective procedure even in patients with CRT-D.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.